NCT03739983
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Other
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older   (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have been receiving aromotase inhibitors (Ais) for at least 6 months prior to enrollment & plan to continue AIs for an additional 3 months
Exclusions:
https://ClinicalTrials.gov/show/NCT03739983